Grigoris Gerotziafas on VTE in MM and BCMA: We Are Pleased to Announce Our New Systematic Review
Grigoris Gerotziafas, Director of the Cancer, Vessels, Biology, and Therapeutics (CaVITE) Research Department, Head of the CRSA at Sorbonne University, shared on LinkedIn
about a recent article he and his colleagues co-authored, adding:
”Venous thromboembolism in patients with multiple myeloma treated with B-cell maturation antigen (BCMA)–directed chimeric antigen receptor (CAR) T-cell therapy: A systematic review.
We are pleased to announce our new systematic review leaded by Dr Pedro Las Casas, Associated Researcher in CaVITE Team – Thrombosis Center (G Gerotziafas), CRSA Sorbonne Univeristy:
This work was conducted by the CaVITE team (CRSA, INSERM, Sorbonne University), in collaboration with expert groups from:
- Hematology Department, University Hospital Morales Meseguer and IMIB/CIBERER, Murcia, Spain
- Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
- Loyola University Stritch School of Medicine, Maywood (IL), USA
- Hospital Papa Giovanni XXIII, Bergamo, Italy
- Thrombosis Center, Department of Obstetrics, Gynecology and Perinatal Medicine, Sechenov University, Moscow, Russia
Key message: The reported incidence of venous thromboembolism (VTE) after BCMA-directed CAR T-cell therapy in multiple myeloma is low, but likely underestimated, particularly in real-world studies.
When thrombotic events are actively sought and systematically documented, VTE rates appear comparable to those expected in relapsed/refractory multiple myeloma patients receiving standard thromboprophylaxis.
These findings emphasize the need for stronger methodological rigor in assessing and reporting thrombotic complications in CAR T-cell therapy, rather than supporting definitive conclusions regarding thrombotic safety or prophylaxis adequacy.
Reference:
Las Casas PHFDC, Marco-Ayala J, Lefkou EE, Soares TS, Baghdadi MA, Kempaiah P, Fareed J, Vandreden P, Hungria V, Marchetti M, Falanga A, Garderet L, Gerotziafas G. Venous thromboembolism in patients with multiple myeloma treated with B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy: A systematic review. Br J Haematol. 2026 Feb 1. doi: 10.1111/bjh.70356. Epub ahead of print. PMID: 41622574.”
Title: Venous thromboembolism in patients with multiple myeloma treated with B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy: A systematic review
Authors: Pedro Henrique Fernandes do Carmo Las Casas, Javier Marco-Ayala, Elmina-Eleftheria Lefkou, Thamiris Silva Soares, Mohammed A. Baghdadi, Prakasha Kempaiah, Jawed Fareed, Patrick Vandreden, Vania Hungria, Marina Marchetti, Anna Falanga, Laurent Garderet, Grigoris Gerotziafas
Read the Full Article on BJHaem
Stay updated on all scientific advances with Hemostasis Today.
-
Mar 20, 2026, 17:47Julie Rayes: Commenting on a Seminal NEJM Study Solving the Mystery of VITT
-
Mar 20, 2026, 17:45William Tembo: Advancing Stroke Care by Validating Acute Ischemic Treatment
-
Mar 20, 2026, 17:37Renjith Vijayakumar Selvarani: New Nanoparticle Approach Clears Brain Plaque and Restores Memory
-
Mar 20, 2026, 17:35Bawan Ahmed: New Evidence May Shift DOAC Choice in Acute DVT Management
-
Mar 20, 2026, 17:17Angelo Cascio Rizzo: CTA-Based Plaque RADS Improves Risk Stratification in ESUS
-
Mar 20, 2026, 17:09Clinical Practice Guidelines for Platelet Transfusion in Non-Surgical and Non-Traumatic Settings – CEBaP
-
Mar 20, 2026, 17:07The Rich Heterogeneity of Platelets and Its Vital Shifts Across Disease States – RPTH
-
Mar 20, 2026, 17:05Pierre Fontana: Launching the European Interuniversity Certificate in Clinical Haemostasis
-
Mar 20, 2026, 16:49Wolfgang Miesbach: A Pivotal Step Forward for Patients with von Willebrand Disease Across All Subtypes